End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24.17 CNY | -0.70% | +2.11% | -3.44% |
May. 10 | Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets | MT |
May. 09 | Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.44% | 8.04B | A | ||
+30.38% | 684B | C+ | ||
+26.51% | 568B | B | ||
-4.36% | 361B | C+ | ||
+19.30% | 329B | B- | ||
+3.73% | 284B | C+ | ||
+16.70% | 240B | B+ | ||
+8.78% | 208B | B- | ||
-7.93% | 200B | A+ | ||
+7.68% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600196 Stock
- Ratings Shanghai Fosun Pharmaceutical (Group) Co., Ltd.